PRNewswire - November 13, 2002

This is the fourth patent issued by the USPTO to Pharmacor within a year. Of those, three cover anti-protease families of compounds and one covers an anti-integrase family of compounds. Additional HIV inhibitor patents are pending.

"Our technology platform is based on the use of simple, original molecular scaffolds on which chemical groups are attached in a few easy steps to generate powerful protease inhibitors," notes Dr. Jocelyn Yelle, V.P. of R&D. "Our urea derivative compounds are the result of this approach."

"A study published in the New England Journal of Medicine in August reports a dramatic increase in the incidence of patients on drug therapy that are experiencing drug or multi-drug resistance," states Dr. Brigitte Lebreton, President and CEO of Pharmacor. "And, up to 20% of newly diagnosed HIV- infected patients are now presenting with drug resistance. We are addressing this unmet medical need by developing drug compounds with unique resistance profiles in order to treat these patients."

There are currently 15 AIDS drugs on the market, but as many as 50% of the patient population has developed drug or multi-drug resistance to one or more of these drugs. Theoretically, all patients will show some form of drug resistance due to the nature of the virus, creating demand for a variety of treatment options.

Pharmacor Inc. is a Montreal-based biopharmaceutical company committed to the discovery and development of innovative therapeutic agents for the treatment of HIV/AIDS. Pharmacor's robust antiviral drug pipeline consists of novel, small-molecule compounds with unique resistance profiles and novel mechanisms of action. The Company's HIV portfolio includes: novel protease inhibitors with unique resistance profiles, in preclinical trials and a new family of anti-HIV drugs that inhibit integrase activity. Although Pharmacor is a publicly held company, its shares are not publicly traded, nor listed on any stock exchange. Visit us at: http://www.pharmacor.com .

This news release contains forward-looking statements including technology development efforts and expectations, as well as the Company's technologies and strategies. The actual results may differ materially from those projected in the forward-looking statements due to numerous risks and uncertainties that exist in the Company's operations, development efforts and the business environment, including without limitation: the ability to deliver its products to corporate collaborators; the progress of product research and development activities; the ability to enter into future collaborations with pharmaceutical and biotechnology companies. The forward-looking statements contained herein represent the judgment of Pharmacor Inc. as of the date of this release. Pharmacor Inc. disclaims any intent or obligation to update any forward-looking statements except to the extent required by law.

SOURCE Pharmacor Inc.

021113
PR021117

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .